Engineered immune cells take aim at childhood cancer
NCT ID NCT02311621
First seen May 21, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This early-stage study tests whether a patient's own immune cells, modified in a lab to recognize and attack neuroblastoma cells, are safe and tolerable. Up to 65 children and young adults with recurrent or treatment-resistant neuroblastoma will receive these engineered T-cells. The main goal is to find the highest safe dose and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.